SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below key support levels are dominating discussion, with traders pointing to leveraged-long liquidations and broader risk-off pressure across crypto and tech as possible contributors. The community is split between warnings of further downside and calls to buy an oversold dip or watch for support.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas reiterated that topline results from its Phase 3 REGAL trial of GPS in AML are expected in November after the trial reached its required event milestone, drawing attention to the pending binary readout. Traders are broadly excited about the prospect of positive data and a short squeeze, while speculation about a leak or buyout remains unconfirmed and skeptics stress that results have not been released and the trial outcome is uncertain.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints about work interruptions and concern that the prolonged disruption could damage trust or pressure the stock. Some traders speculated about a cyberattack, but the cause was not confirmed, and others questioned why shares held relatively steady.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp decline toward the $1 support level amid a broader crypto selloff is dominating discussion, with traders pointing to Bitcoin weakness, inflation and rate concerns, and liquidations. Bears warn of further downside and question Ripples ability to provide catalysts, while some holders view the drop as a buying opportunity and continue accumulating.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Weakness in Ethereum and broader crypto-linked stocks is weighing on BitMine, while traders also criticize its underperformance and question managements spending, transparency, and buybacks. Some see the stocks discount to its crypto holdings as a buying opportunity, but bearish posts argue falling ETH prices can overwhelm any support from repurchases.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure as Bitcoin and broader crypto markets sell off, with traders highlighting COINs repeated new lows and weak performance even when Bitcoin stabilizes. Bearish calls dominate, though some see the decline as oversold and are buying the dip.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rs 325–4,200/month: Dr Reddy’s, Sun Pharma, Glenmark kick off generic semaglutide price war

… Reddy’s Laboratories, Sun Pharma , Glenmark Pharmaceuticals , Alkem Laboratories, Zydus Lifesciences … , and Natco Pharma . Eris Lifesciences, which has a … first Indian pharma company to receive approval from the Drugs Controller General …

India’s Eris launches $14 monthly generic Ozempic shot, among cheapest globally

India’s Eris Lifesciences on Friday launched one of the most affordable versions of Ozempic so far, with the lowest dosage of generic semaglutide starting at 1,290 rupees ($13.8) per month. Launch under the brand Sundae in India for diabetes, with lowest dose of a Sundae vial, at 2 mg. Natco Pharma, Eris’ partner for the semaglutide launch, priced its lowest 2 mg dose at 1,290 rupees a month. Eris also plans to launch a pen device version of Sundae in April, in three dosages. The lowest 2 mg dose will cost 4,000 rupees per month and the highest 8 mg dose 4,500 rupees per month. Eris is among dozens of Indian drugmakers that are launching generic semaglutide as Danish drugmaker Novo Nordisk’s semaglutide patent is set to expire on March 20. Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India Larger peer Dr Reddy’s is expected to launch on Saturday. Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.

Eris Lifesciences, Natco Pharma ink pact on Semaglutide

Eris Lifesciences has forged a strategic partnership with Natco Pharma for commercialisation of semaglutide in India.

Eris Lifesciences Ltd announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India

… strategic partnership with Natco Pharma Limited for the commercialisation … Natco Pharma has received approval from the Central Drugs Standard … Bulls Keywords ErisLifesciences INE406M01024 Pharmaceuticals Partnership NatcoPharma Semaglutide IndiaLaunch

Natco Pharma, Eris Lifesciences shares jump up to 6% on partnership for Semaglutide launch in India

Shares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco rose over 6% to its highest level since January 8, while Eris gained nearly 4%, marking its third straight session of gains.

Eris Lifesciences partners Natco to commercialise semaglutide

Eris Lifesciences has partnered with Natco Pharma to introduce semaglutide in the Indian market a cutting-edge therapy for Type 2 diabetes and obesity management. By combining Eris’s strong commercial network with Natco’s proven production capabilities, the alliance expands Eris’s diabetes care portfolio with a high-impact, next-generation treatment.

Eris Lifesciences/Natco Pharma partner on semaglutide for India

Natco Pharma has received regulatory approval in India, paving the way for a launch in March 2026

Brief India: Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY and more

In this briefing: Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY ICICI Prudential AMC (ICICIAMC IN): Partial Global Index Inclusion with Low Float What Does Silver's Volatility Mean for Markets? Auto Sector Update: India EU FTA Update 1. Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY Overall B2C GOV grew 49% YoY (8.6% QoQ) to reach INR 181.2bn (in-line) Consolidated adj EBITDA losses stood at INR7.1bn (in-line) Food delivery (FD) GOV grew 20.5% YoY to INR 89.6bn (HSIE: INR 88bn) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2. Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x and PE of 24x for ex-amortization EPS), as we believe since our downgrade to ADD in Jul-25, the stock price has corrected (down 25% in the last six months), which factors in the growth concern in key therapies Now, the valuation has turned attractive (trading at 36/ 26/ 21x on FY25/26/27E PE vs its 5-year average of ~25x) and is providing comfort We expect Eris to focus on the execution phase after its aggressive investments (multiple M&As over FY23–25 and invested INR 38–40bn) for the next few years with focus on anti-diabetic (insulins), obesity (GLP-1) categories, and new FDC launches (~20+ in FY27) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY and more

In this briefing: Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY ICICI Prudential AMC (ICICIAMC IN): Partial Global Index Inclusion with Low Float What Does Silver's Volatility Mean for Markets? Auto Sector Update: India EU FTA Update Union Budget 2026- What We like and What We Don't 1. Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x and PE of 24x for ex-amortization EPS), as we believe since our downgrade to ADD in Jul-25, the stock price has corrected (down 25% in the last six months), which factors in the growth concern in key therapies Now, the valuation has turned attractive (trading at 36/ 26/ 21x on FY25/26/27E PE vs its 5-year average of ~25x) and is providing comfort We expect Eris to focus on the execution phase after its aggressive investments (multiple M&As over FY23–25 and invested INR 38–40bn) for the next few years with focus on anti-diabetic (insulins), obesity (GLP-1) categories, and new FDC launches (~20+ in FY27) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Medical Community joins forces on Republic day to address the Silent Crisis of Hypertension at One India Conclave

• Unveils India’s First Hypertension Anthem • National Doctors’ Movement Gains Momentum to Bridge the Diagnosis-to-Control Gap Across India MUMBAI, India, Jan. 27, 2026 /PRNewswire/ — Marking the 77th Republic Day with a call for national health unity, Eris Lifesciences hosted the One India Conclave to address the growing crisis of hypertension in the country. […]

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. Its brands include Eritel, Glimsave, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The firm markets and distributes pharmaceutical drugs, such as tablets, syrups and injections. The company was founded by Amit Indubhushan Bakshi on January 25, 2007 and is headquartered in Ahmedabad, India.

Current Price	1,337.20
Prev Close	1,277.00
Open	1,274.80
Dividend Yield	0.00%
50-Day Moving Average	1,221.16
Beta	N/A
Avg. Volume	126,671.05
PE Ratio	24.83

52-Week High	1,740.00
52-Week Low	1,069.00
Market Capitalization	176.8B
EPS (Annual)	45.33
Price to Book	4.28
Revenue Per Employee	10.17M

Feed

News

Sentiment

Fundamentals

Info

ERIS.NSE Fundamentals